Transaction DateRecipientSharesTypePriceValue
1st October 2020Stanley C Erck2Open or private sale$108.57$217.13
30th September 2020Stanley C Erck800Open or private sale$114.73$91,784.00
30th September 2020Stanley C Erck517Open or private sale$107.56$55,608.99
30th September 2020Stanley C Erck1,676Open or private sale$110.54$185,269.73
30th September 2020Stanley C Erck5,138Open or private sale$108.56$557,796.69
30th September 2020Stanley C Erck1,500Open or private sale$109.54$164,304.00
30th September 2020Stanley C Erck800Open or private sale$112.65$90,118.00
30th September 2020Stanley C Erck100Open or private sale$115.65$11,565.00
30th September 2020Stanley C Erck100Open or private sale$115.43$11,543.00
30th September 2020Stanley C Erck700Open or private sale$114.20$79,940.00
Novavax
Novavax logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.


Novavax, Inc. is a late-stage biotechnology company. It focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. Its vaccine candidates include ResVax and NanoFlu.


Ticker: NVAX
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1000694
Employees: 379
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $424 M (0%)
Assets, Current: $636 M (554%)
Property, Plant and Equipment, Net: $115 M (908%)
Other Assets, Noncurrent: $56 M (685%)
Assets: $932 M (438%)
Accounts Payable, Current: $9 M (217%)
Accrued Liabilities, Current: $39 M (160%)
Liabilities, Current: $213 M (727%)
Other Liabilities, Noncurrent: $11 M (6%)
Liabilities: $548 M (52%)
Common Stock, Value, Issued: $612 Th (88%)
Common Stock, Shares, Issued: $61 M (89%)
Retained Earnings (Accumulated Deficit): $1 B (4%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $13 M (5%)
Treasury Stock, Value: $26 Th (2%)
Treasury Stock, Shares: $514 Th (9%)
Stockholders' Equity (Parent): $185 M (0%)
Liabilities and Equity: $932 M (438%)
Research and Development: $35 M (-32%)
General and Administrative Expenses: $18 M (-34%)
Operating Income/Loss: $17 M (-57%)